<DOC>
	<DOCNO>NCT00779831</DOCNO>
	<brief_summary>Compare bioavailability Pseudoephedrine hydrochloride extend release tablet ( Ranbaxy Laboratories Limited ) reference product Sudafed Â® 12-hour tablet 120 mg ( Warner-Lambert ) fasting condition .</brief_summary>
	<brief_title>Bioequivalence Study Pseudoephedrine HCl 120 mg ER Tablets Under Fasting Conditions</brief_title>
	<detailed_description>This open label , randomize , single dose , 2-way crossover , relative bioavailability study perform total 36 healthy adult subject ( 20 male 16 female ) . Thirty five ( 35 ) subject ( 19 male 16 female ) complete clinical phase study . In period , subject house least 10 hour dose 36 hour blood draw . Single oral 120 mg Pseudoephedrine hydrochloride dos separate washout period 7 day . A total thirty six ( 36 ) subject ( 20 male 16 female ) enrol study . Out total thirty five ( 35 ) subject ( 19 male 16 female ) complete clinical phase study .</detailed_description>
	<mesh_term>Pseudoephedrine</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<criteria>All subject enrol study meet inclusion exclusion criterion , judge investigator normal , healthy volunteer Subjects include study meet follow criterion : 1 . Healthy adult male female volunteer , 18 55 year age 2 . Weighing least 52 kg male 45 kg female within 15 % ideal weight ( table 'Desirable Weights Adults ' , Metropolitan Life Insurance Company , 1983 ) 3 . Medically healthy subject clinically normal laboratory profile ECGs 4 . Females child bear potential either sexually inactive ( abstinent ) 14 day prior first dose throughout study use one follow acceptable birth control method : 1 . Surgically sterile ( bilateral tubal ligation , hysterectomy , bilateral oophorectomy ) 6 month minimum 2 . IUD place least 3 month 3 . Barrier method ( condom , diaphragm ) spermicide least 14 day prior first dose throughout study 4 . Surgical sterilization partner ( vasectomy 6 month minimum ) 5 . Hormonal contraceptive least 3 month prior first dose study 6 . Other birth control method may deem acceptable 5 . Post menopausal woman amenorrhea least 2 year eligible 6 . Voluntarily consent participate study Subjects exclude study evidence follow screening time study : 1 . History presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease 2 . In addition , history presence : 1 . Alcoholism drug abuse within past year 2 . Hypersensitivity idiosyncratic reaction Pseudoephedrine sympathomimetic amine 3 . Glaucoma hypermetropia 3 . Female subject pregnant lactate 4 . Positive result HIV , HbsAg HCV test 5 . Subjects receive monoamine oxidase ( MAO ) inhibitor within 14 day stop use MAO inhibitor , sympathomimetic amine 6 . Subjects special diet ( whatever reason ) 28 day prior first dose throughout study 7 . Subjects completion study , would donate excess : 500 mL blood 14 day 1500 mL blood 180 day 2500 mL blood 1 year . 8 . Subjects participate another clinical trial within 28 day prior first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Bioequivalence Pseudoephedrine hydrochloride 120 mg extend release tablet</keyword>
</DOC>